Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWeight loss injections like Mounjaro and Wegovy do reduce appetite, but appetite suppression is only part of the picture. These medicines activate gut-hormone receptors that influence blood-sugar regulation, gastric emptying, and how the brain registers fullness — effects that work together, not in isolation. They are prescription-only medicines, and a prescriber decides whether they are clinically appropriate for you. If you have been wondering whether appetite alone explains the results seen in clinical trials, the honest answer is no — and understanding why changes how you think about treatment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
It is a reasonable question, and a common one. If you have been sceptical about GLP-1 medicines because they sound like a glorified appetite suppressant, you are in good company. The assumption is that eating less is eating less, regardless of what triggers it, so what difference does the mechanism make?
Quite a lot, as it turns out. Appetite reduction is real and significant, but framing these medicines purely as appetite suppressants misses the biology. Both semaglutide (Wegovy) and tirzepatide (Mounjaro) work by mimicking gut hormones that your body already produces in response to eating. GLP-1 (glucagon-like peptide-1) is released naturally after a meal; it signals fullness to the brain, slows gastric emptying, and helps regulate blood sugar by stimulating insulin release. These processes are interlinked. Slowing gastric emptying does reduce hunger, but it also means glucose enters the bloodstream more gradually, which smooths out the blood-sugar spikes and crashes that can drive cravings later in the day.
Tirzepatide goes further still, also activating GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP has its own role in fat storage and energy metabolism, which is why the dual mechanism produces meaningfully different results from a single-pathway medicine. Our overview of weight loss injections covers both medicines side by side if you want to compare the two before your consultation.
The gastric-emptying effect is worth dwelling on. Meals leave the stomach more slowly, so the physical sensation of being full lasts longer. This is separate from the brain's appetite signalling, it is a mechanical change in how your digestive system processes food. For many people, this means smaller portions feel genuinely satisfying rather than like a willpower exercise.
At the same time, the hypothalamus receives clearer satiety signals through the GLP-1 pathway. Research points to reduced activity in brain regions associated with food reward, the impulse to eat for pleasure rather than hunger. That shift is not the same as suppressing appetite in the way an older stimulant-based diet pill might: there is no central nervous system stimulation, no jitteriness. The change is quieter than that.
Blood-sugar regulation sits underneath all of this. Even in people without diabetes, smoother insulin response means fewer energy troughs, which reduces the urge to reach for something sweet mid-afternoon. If you have ever wondered whether weight loss injections truly suppress your appetite or whether something more complex is happening, the blood-sugar angle is a good place to start. These biological effects are also why these medicines are used in the management of type 2 diabetes under different brand names, the mechanisms overlap, even if the licensed indications differ.
Clinical results reflect the combined picture. The STEP 1 trial of semaglutide 2.4mg reported an average weight reduction of around 15% over 68 weeks, as published in the New England Journal of Medicine. SURMOUNT-1 reported roughly 20–21% at the highest tirzepatide dose. Neither figure is explained by appetite suppression in isolation.
Understanding the mechanism helps set realistic expectations. Patients often describe a shift in their relationship with food rather than a simple switch-off of hunger. Meals become less preoccupying. The pull toward snacking diminishes. It is not that food stops being enjoyable, it is that the urgency fades.
This also matters for how you support treatment. Because gastric emptying slows, prioritising protein and fibre at meals helps maintain muscle and keeps digestion comfortable. Hydration matters more than people expect, partly because the gastrointestinal side effects (nausea, constipation) are most common in the first few weeks and are largely manageable with the right habits. You can read more about what to expect day-to-day on our weight loss injection guide.
The NHS describes these effects clearly in its patient information for tirzepatide, confirming that the medicine works through appetite, gastric emptying, and blood-sugar regulation together. None of these effects replaces the role of a reduced-calorie diet and increased activity, the licence for both Mounjaro and Wegovy specifies they are prescribed alongside lifestyle changes, not instead of them. Ongoing clinical support makes a real difference to how confidently people manage that combination.
Both medicines are licensed for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds may apply for some ethnic backgrounds under UK guidance. BMI alone does not determine suitability, a prescriber weighs the full clinical picture, including your medical history and any medicines you already take.
Pregnancy, breastfeeding, and actively trying to conceive are contraindications; these medicines are not licensed for under-18s either. If you take the oral contraceptive pill and start tirzepatide specifically, NHS guidance recommends adding a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase, because pill absorption may be reduced. NICE's appraisal of tirzepatide (TA1026) sets out the evidence base behind the recommendation. A prescriber at a regulated service works through these details with you before anything is prescribed.
If you are thinking about the cost of treatment alongside the clinical picture, our weight loss injections cost page explains what private treatment typically includes. Speak to our prescribers through a free consultation if you want a clinical view on whether these medicines are right for your situation, and if you would like more detail on how the injected format works, our page on the weight loss appetite suppressant injection covers the practicalities in full.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.